These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 27379436)

  • 1. Chemotherapy use and adoption of new agents is affected by age and comorbidities in patients with metastatic colorectal cancer.
    Vijayvergia N; Li T; Wong YN; Hall MJ; Cohen SJ; Dotan E
    Cancer; 2016 Oct; 122(20):3191-3198. PubMed ID: 27379436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemotherapy compliance, tolerance and efficacy in elderly and non-elderly patients with metastatic colorectal cancer: a single institution comparative study.
    Bakogeorgos M; Mountzios G; Kotsantis G; Economopoulou P; Fytrakis N; Kentepozidis N
    J BUON; 2013; 18(3):629-34. PubMed ID: 24065475
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment patterns and metastasectomy among mCRC patients receiving chemotherapy and biologics.
    Song X; Zhao Z; Barber B; Gregory C; Wang PF; Long SR
    Curr Med Res Opin; 2011 Jan; 27(1):123-30. PubMed ID: 21128878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronomodulated irinotecan, oxaliplatin, and leucovorin-modulated 5-Fluorouracil as ambulatory salvage therapy in patients with irinotecan- and oxaliplatin-resistant metastatic colorectal cancer.
    Gholam D; Giacchetti S; Brézault-Bonnet C; Bouchahda M; Hauteville D; Adam R; Ducot B; Ghémard O; Kustlinger F; Jasmin C; Lévi F
    Oncologist; 2006; 11(10):1072-80. PubMed ID: 17110626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis for prognostic factors of 60-day mortality: evaluation of an irinotecan-based phase III trial performed in the first-line treatment of metastatic colorectal cancer.
    Giessen C; Stintzing S; Laubender RP; Ankerst DP; Schulz C; Moosmann N; Modest DP; Schalhorn A; von Weikersthal LF; Heinemann V
    Clin Colorectal Cancer; 2011 Dec; 10(4):317-24. PubMed ID: 21729676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response to chemotherapy in metastatic colorectal cancer after exposure to oxaliplatin in the adjuvant setting.
    Moreau LC; Rajan R; Thirlwell MP; Alcindor T
    Anticancer Res; 2013 Apr; 33(4):1765-8. PubMed ID: 23564831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative effectiveness of chemotherapy in elderly patients with metastatic colorectal cancer.
    Satram-Hoang S; Lee L; Yu S; Guduru SR; Gunuganti AR; Reyes C; McKenna E
    J Gastrointest Cancer; 2013 Mar; 44(1):79-88. PubMed ID: 23132351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High- versus low-dose leucovorin in the modified FOLFOX6 regimen for first-line treatment of metastatic colorectal cancer.
    Reynolds J; Chamberland-Tremblay A; Herrington JD; Munoz Maldonado Y; Wong L
    J Oncol Pharm Pract; 2017 Apr; 23(3):173-178. PubMed ID: 26786027
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronological Age and Risk of Chemotherapy Nonfeasibility: A Real-Life Cohort Study of 153 Stage II or III Colorectal Cancer Patients Given Adjuvant-modified FOLFOX6.
    Laurent M; Des Guetz G; Bastuji-Garin S; Culine S; Caillet P; Aparicio T; Audureau E; Carvahlo-Verlinde M; Reinald N; Tournigand C; Landre T; LeThuaut A; Paillaud E; Canouï-Poitrine F
    Am J Clin Oncol; 2018 Jan; 41(1):73-80. PubMed ID: 26669742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Durable complete responses in metastatic colorectal cancer treated with chemotherapy alone.
    Ferrarotto R; Pathak P; Maru D; Agarwal A; Overman M; Hoff PM; Kopetz S
    Clin Colorectal Cancer; 2011 Sep; 10(3):178-82. PubMed ID: 21855039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [KRAS mutation does not influence oxaliplatin or irinotecan efficacy, in association with bevacizumab, in first line treatment of metastatic colorectal cancer].
    Cabart M; Frénel JS; Campion L; Ramée JF; Dupuis O; Senellart H; Hiret S; Douillard JY; Bennouna J
    Bull Cancer; 2016 Jun; 103(6):541-51. PubMed ID: 27155924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial.
    Rothenberg ML; Oza AM; Bigelow RH; Berlin JD; Marshall JL; Ramanathan RK; Hart LL; Gupta S; Garay CA; Burger BG; Le Bail N; Haller DG
    J Clin Oncol; 2003 Jun; 21(11):2059-69. PubMed ID: 12775730
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Irinotecan/5-FU/leucovorin, oxaliplatin/5-FU/leucovorin, and oxaliplatin/irinotecan are each effective in the treatment of 5-FU-resistant advanced colorectal cancer.
    Fisher MD
    Clin Colorectal Cancer; 2001 Aug; 1(2):85-6. PubMed ID: 12445365
    [No Abstract]   [Full Text] [Related]  

  • 14. S-1 and irinotecan with or without bevacizumab versus 5-fluorouracil and leucovorin plus oxaliplatin with or without bevacizumab in metastatic colorectal cancer: a pooled analysis of four phase II studies.
    Iwasa S; Nagashima K; Yamaguchi T; Matsumoto H; Ichikawa Y; Goto A; Yasui H; Kato K; Okita NT; Shimada Y; Yamada Y
    Cancer Chemother Pharmacol; 2015 Sep; 76(3):605-14. PubMed ID: 26220845
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of dose/time modification in irinotecan- and oxaliplatin-based chemotherapies on outcomes in metastatic colorectal cancer.
    Nakayama G; Tanaka C; Uehara K; Mashita N; Hayashi N; Kobayashi D; Kanda M; Yamada S; Fujii T; Sugimoto H; Koike M; Nomoto S; Fujiwara M; Ando Y; Kodera Y
    Cancer Chemother Pharmacol; 2014 Apr; 73(4):847-55. PubMed ID: 24577566
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Maintenance of the nutritional prognostic index predicts survival in patients with unresectable metastatic colorectal cancer.
    Ikeya T; Shibutani M; Maeda K; Sugano K; Nagahara H; Ohtani H; Hirakawa K
    J Cancer Res Clin Oncol; 2015 Feb; 141(2):307-13. PubMed ID: 25124497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial.
    Goldberg RM; Sargent DJ; Morton RF; Fuchs CS; Ramanathan RK; Williamson SK; Findlay BP; Pitot HC; Alberts S
    J Clin Oncol; 2006 Jul; 24(21):3347-53. PubMed ID: 16849748
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FOLFIRINOX bevacizumab is a promising therapy for chemorefractory metastatic colorectal cancer.
    Chaix M; Vincent J; Lorgis V; Ghiringhelli F
    Oncology; 2014; 87(3):148-58. PubMed ID: 25012455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimal Sequence of Irinotecan and Oxaliplatin-Based Regimens in Metastatic Colorectal Cancer: A Population-Based Observational Study.
    Teng CL; Wang CY; Chen YH; Lin CH; Hwang WL
    PLoS One; 2015; 10(8):e0135673. PubMed ID: 26273837
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II randomized study of combined infusional leucovorin sodium and 5- FU versus the leucovorin calcium followed by 5-FU both in combination with irinotecan or oxaliplatin in patients with metastatic colorectal cancer.
    Bleiberg H; Vandebroek A; Deleu I; Vergauwe P; Rezaei Kalantari H; D'Haens G; Paesmans M; Peeters M; Efira A; Humblet Y
    Acta Gastroenterol Belg; 2012 Mar; 75(1):14-21. PubMed ID: 22567742
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.